Foerch Christian, Sitzer Matthias, Steinmetz Helmuth, Neumann-Haefelin Tobias
Department of Neurology, Goethe University, Frankfurt am Main, Germany.
Stroke. 2009 May;40(5):1900-2. doi: 10.1161/STROKEAHA.108.531061. Epub 2009 Feb 26.
Thrombolytic therapy with tissue plasminogen activator (tPA) is rarely applied to ischemic stroke patients aged 80 years and above. As future demographic trends will increase the proportion of older stroke patients, the overall tPA treatment rate may decrease. The aim of the present analysis was to provide an estimate of the future number of ischemic stroke patients and the fraction thereof receiving tPA.
In 2005, n=12 906 hospitalized ischemic stroke patients were included into a large registry covering the Federal State of Hesse, Germany. Age- and gender-specific frequency rates for ischemic stroke and tPA therapy were calculated based on the registry and the respective population data. Population projections until 2050 were derived from the Hessian Bureau of Statistics.
Assuming constant age- and gender-specific stroke incidence rates and treatment strategies, the total number of ischemic stroke patients will rise by approximately 68% until 2050, whereas the proportion of tPA-treated ischemic stroke patients will decrease from 4.5% to 3.8% in the same time frame (relative decrease 16%; chi(2) P<0.001).
Future demographic changes will reduce tPA treatment rates. Therapeutic studies focusing on very old stroke patients are necessary to counteract this trend.
组织型纤溶酶原激活剂(tPA)溶栓治疗很少应用于80岁及以上的缺血性脑卒中患者。由于未来人口趋势将使老年脑卒中患者比例增加,tPA的总体治疗率可能会下降。本分析的目的是估计未来缺血性脑卒中患者的数量及其接受tPA治疗的比例。
2005年,n = 12906例住院缺血性脑卒中患者被纳入一个覆盖德国黑森州的大型登记系统。基于该登记系统和相应的人口数据,计算了缺血性脑卒中和tPA治疗的年龄及性别特异性发病率。直至2050年的人口预测数据来自黑森州统计局。
假设年龄及性别特异性脑卒中发病率和治疗策略保持不变,到2050年缺血性脑卒中患者总数将增加约68%,而同期接受tPA治疗的缺血性脑卒中患者比例将从4.5%降至3.8%(相对下降16%;卡方检验P<0.001)。
未来人口结构变化将降低tPA治疗率。有必要开展针对高龄脑卒中患者的治疗研究以应对这一趋势。